首页> 外文期刊>Clinical and Experimental Immunology: An Official Journal of the British Society for Immunology >A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
【24h】

A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.

机译:一种用于肺癌的基于树突细胞的肿瘤疫苗:全长XAGE-1b蛋白脉冲的树突细胞可在体外诱导特定的细胞毒性T淋巴细胞。

获取原文
获取原文并翻译 | 示例
           

摘要

XAGE-1b is regarded as one of the most immunogenic antigens and the most promising targets for lung adenocarcinoma immunotherapy. In this study, we sought to determine whether monocyte-derived dendritic cells (DCs) pulsed with purified full-length XAGE-1b could induce specific cytotoxic T lymphocytes (CTLs) against tumour cells from patients with non-small cell lung cancer (NSCLC) in vitro. XAGE-1b mRNA expression was examined in primary cultures of lung cancer cells and normal lung epithelial cells established from fresh tissues surgically resected from 30 patients with NSCLC using reverse transcription-polymerase chain reaction (RT-PCR). XAGE-1b mRNA expression was observed in 11 of 18 (61.1%) adenocarcinomas and one of 12 (8.3%) lung cancers of other histological types (P = 0.015). The 246-base pairs XAGE-1b gene was inserted into a recombinant expression vector. Full-length XAGE-1b was then expressed in BL21 (DE3) Escherichia coli and purified by AKTA-fast performance liquid chromatography (FPLC). DCs generated from peripheral blood mononuclear cells were pulsed with XAGE-1b by incubation with the protein at an immature stage. The XAGE-1b-pulsed DCs induced CTLs following 14 days of co-culture. Finally, an adherent target detachment (ATD) assay was performed to test the cytotoxicity of the XAGE-1b-specific CTLs against cancer cells and normal lung epithelial cells. The XAGE-1b-specific CTLs had a stronger lytic effect on autologous XAGE-1b mRNA-positive cancer cells than on autologous XAGE-1b mRNA-negative cancer cells or allogenous XAGE-1b mRNA-positive cancer cells. The CTLs had no lytic activity against normal lung epithelial cells. These results can be used to develop simple and effective cancer/testis antigen-based immunotherapies for NSCLC.
机译:XAGE-1b被认为是肺腺癌免疫疗法中最具免疫原性的抗原和最有希望的靶标之一。在这项研究中,我们试图确定用纯化的全长XAGE-1b脉冲产生的单核细胞来源的树突状细胞(DC)是否可以诱导针对非小细胞肺癌(NSCLC)患者肿瘤细胞的特异性细胞毒性T淋巴细胞(CTL)。体外。使用逆转录-聚合酶链反应(RT-PCR)检测了肺癌细胞和正常肺上皮细胞的原代培养物中的XAGE-1b mRNA表达。 XAGE-1b mRNA表达在其他组织学类型的18个腺癌中有11个(61.1%)和12个(8.3%)肺癌之一中被观察到(P = 0.015)。将246个碱基对的XAGE-1b基因插入重组表达载体中。然后在BL21(DE3)大肠杆菌中表达全长XAGE-1b,并通过AKTA快速高效液相色谱(FPLC)进行纯化。通过在未成熟阶段与蛋白质孵育,用XAGE-1b脉冲从外周血单核细胞产生的DC。共培养14天后,XAGE-1b脉冲的DC诱导了CTL。最后,进行粘附靶标脱离(ATD)试验以测试XAGE-1b特异性CTL对癌细胞和正常肺上皮细胞的细胞毒性。与自体XAGE-1b mRNA阴性癌细胞或异体XAGE-1b mRNA阳性癌细胞相比,XAGE-1b特异的CTL对自体XAGE-1b mRNA阳性癌细胞具有更强的裂解作用。 CTL对正常的肺上皮细胞没有溶解活性。这些结果可用于为NSCLC开发简单有效的基于癌症/睾丸抗原的免疫疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号